✦ LIBER ✦

Reduction of Fear and Acute Toxicity From Chemotherapy With a Telephone Call After the First Cycle

✍ Scribed by Mordenti, Patrizia; Capuano, Donato L.; Zanlari, Luca; Achilli, Raffaella; Galli, Maria L.; Marazzi, Elisabetta; Gandolfi, Sonia; Granelli, Barbara; Terzoni, Daniela; Civardi, Giuseppe; Cavanna, Luigi

Book ID: 122472326
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 354 KB
Volume: 46
Category: Article
ISSN: 0885-3924
DOI: 10.1016/j.jpainsymman.2013.02.026

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Geriatric screening results and the asso

Geriatric screening results and the association with severe treatment toxicity after the first cycle of (radio)chemotherapy

✍ Baitar, Abdelbari; Van Fraeyenhove, Frank; Vandebroek, An; De Droogh, Els; Galde 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 256 KB

First-cycle rash and survival in patient

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study

✍ Ulrich Gatzemeier; Joachim von Pawel; Ihor Vynnychenko; Petr Zatloukal; Filippo 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 220 KB

Outcome after first relapse in children

Outcome after first relapse in children with acute lymphoblastic leukemia: A population-based study of 315 patients from the nordic society of pediatric hematology and oncology (NOPHO)

✍ Schroeder, H. ;Garwicz, S. ;Kristinsson, J. ;Siimes, M. A. ;Wesenberg, F. ;Gusta 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 532 KB

## Abstract This study reports the outcome after relapse of acute lymphoblastic leukemia (ALL) in a population‐based study of 809 children over 1 year of age diagnosed July 1981 through June 1986 and with non‐B acute lymphoblastic leukemia in the five Nordic countries. By January 1994, 315 children

Case mix, outcome and activity for patie

Case mix, outcome and activity for patients with severe acute kidney injury during the first 24 hours after admission to an adult, general critical care unit: application of predictive models from a secondary analysis of the ICNARC Case Mix Programme Database

✍ Nitin V Kolhe,Paul E Stevens,Alex V Crowe,Graham W Lipkin… 📂 Article 📅 2008 🏛 Springer (Biomed Central Ltd.) 🌐 English ⚖ 588 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB

ANNOUNCEMENTS: 4th Annual Meeting of the

ANNOUNCEMENTS: 4th Annual Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT) The Marriott, Irvine, CA, USA 28–31 January 1999, Keystone Symposia Ocular Cell & Molecular Biology (OCMB) Announces Dean Bok, Ph.D. as the winner of the first OCMB Prize, Keystone OCMB Symposium, 1999 Keystone Colorado 5–10 February 1999, Call for Abstracts and Registration Organizers: Steven E. Wilson and Joe Hollyfield Registration and Abstract Forms available from: Keystone Symposia on Molecular and Cellular Biology Drawer 1630 Silverthorn, Colorado 80498 Telephone: 800-253-0685 Fax: 970-262-1525 E-mail: [email protected], XIV International Congress of Eye Research Santa Fe, New Mexico 15–20 October 2000, XV International Congress of Eye Research (2002) Proposals for the International Congress of Eye Research meeting to be held in the year 2002 are now being accepted by the ISER Council. The Jules François Prize of the Belgian Ophthalmological Societies 2000 The aim of the Jules François Prize is to encourage scientific research in ophthalmology. The prize of 10.000 U.S. Dollars will be awarded to a young scientist who has made an important contribution to ophthalmology. Eligibility: All topics in the field of fundamental and/or clinical research in ophthalmology will be considered. The application should be sent jointly with a curriculum vitae, the list of all publications and 3 copies of the candidates' 10 most relevant publications. The candidate should not be older than 40 years by 31 December 1999. Mailing Address: Jules François Foundation Secretary Prof. Dr. M. Hanssens Dienst Oogheelkunde De Pintelaan 185 B-9000 Gent, Belgium

📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 235 KB